Thomas Stinchcombe, MD
Enriched profileProfessor of Medicine, Duke University School of Medicine · Duke University School of Medicine
Thomas Stinchcombe is Professor of Medicine, Duke University School of Medicine at Duke University School of Medicine. OpenAlex indexes 415 publications with 13,001 citations (h-index 50); ClinicalTrials.gov lists 18 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 16 Oct 2026
Thomas Stinchcombe, MD, is Professor of Medicine, Duke University School of Medicine. The public record shows 415 publications with 13,001 citations (h-index 50), centered on Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Lung Cancer Diagnosis and Treatment. It also documents an investigator role on 18 registered clinical trials, industry payments reported by 29 companies, 2 NIH-funded awards (2006–2026).
- Most recent indexed publication: 2026 · Research square
- Top research focus: Lung Cancer Treatments and Mutations
- 18 registered trials on ClinicalTrials.gov
- Open Payments reporting from 29 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 28 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 147.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 18 registered studies on ClinicalTrials.gov. The most recent:
- A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
Sponsor: TRIANA Biomedicines, Inc.
- Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Sponsor: Nuvalent Inc.
Industry payments
Updated 16 Oct 2026
29 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20254 payments
- F. Hoffmann-La Roche AGProgram year20253 payments
- AstraZeneca UK LimitedProgram year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
81.9%Kinase inhibitor81.9%Tagrisso52%Alecensa18%Retevmo9%Erlotinib Hcl7%Everolimus7%Mekinist7%Part D<11 patientsNervous system
11.6%Phenothiazine11.6%Prochlorperazine Maleate100%Part D≥17 patientsSensory organs
6.5%Corticosteroid6.5%Dexamethasone100%Part D≥12 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 16 Oct 2026
2 NIH research awards on record, funded 2006–2026 per NIH RePORTER. The latest:
Congress activity
Updated 16 Oct 2026
43 congress contributions (2005–2022) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- 1546P Impact of stratification factors on outcomes in limited-stage small cell lung cancer: Analysis of CALGB 30610 (Alliance)/RTOG 0538
ESMO Congress
ESMO2022Co-authorPoster - Abstract 1671: Evaluation of total PD-1 expression using multi-color flow cytometry in metastatic non-small Cell lung cancer patients treated with multi-neoantigen vector (ADXS-503) alone and in combination of pembrolizumab to assess T-cell & T-cell memory subsets
AACR (meeting unresolved)
AACR2021Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 16 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Alirocumab Plus Cemiplimab in Immunorefractory NSCLC: A Single Arm Phase 2 Study.
Research square
Article2026 - Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005.
Journal of clinical oncology
Clinical Trial2026 - Prevalence and Clinical Characteristics of Germline Epidermal Growth Factor Receptor Mutations in the Southeastern Unites States.
JCO precision oncology
Article2026 - Milademetan in Advanced Solid Tumors with MDM2 Amplification and Wild-type TP53: Preclinical and Phase II Clinical Trial Results.
Clinical cancer research
Clinical Trial2025
Most-cited works
by citation count (OpenAlex)- 01
- 02Lobar or Sublobar Resection for Peripheral Stage IA Non–Small-Cell Lung CancerArticle1,060 citations2023
- 03
- 04
- 05
Network
Updated 16 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/thomas-stinchcombe-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Tom-Stinchcombe-2111195163
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Other
ascopost.com/videos/iaslc-2023-wclc/tom-e-stinchcombe-md-on-nsclc-strategies-for-managing-secondary-primary-disease
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - Other
ilcn.org/thomas-stinchcombe-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ilcn.org ↗ - Other
onclive.com/authors/thomas-e-stinchcombe-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dukecancerinstitute.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dukecancerinstitute.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dukecancerinstitute.org ↗
- Board Certified
Medical Oncology (American Board of Internal Medicine)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dukehealth.org ↗
Editorial & leadership roles
journal and society appointments- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →astro.org ↗
- Associate Editor
Journal of Clinical Oncology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ascopubs.org ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncodaily.com ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →curetoday.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
William Kraus, MD
Duke University School of Medicine
Angeles Secord, MD
Duke University School of Medicine
Virginia Kraus, MD, PhD
Duke University School of Medicine
Neal Ready, MD
Duke University School of Medicine
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
Julie Brahmer, MD
Johns Hopkins University School of Medicine
Enriqueta Felip, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center